Shots:

• The P-II REACH-CDM evaluate the efficacy and safety of AMO-02 (tideglusib) in 56 patients to treat congenital Myotonic Dystrophy in the U.S and Canada with additional sites in Australia- New Zealand- and other countries to be added seeking local approvals
• The REACH-CDM study was designed on the basis of positive P-II data results which were recently published in the peer-reviewed journal Pediatric Neurology.
• AMO-02 is a clinical-stage investigation medicine & in development for the treatment of congenital myotonic dystrophy and has potential use in CNS- neuromuscular and other orphan indications

 ­ Ref: PRNewswire  | Image: The Pharma Letter